INT187888

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2005
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 0.40
Pain Relevance 1.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

phosphatase activity (Pgp) carbohydrate metabolic process (Pgp) molecular_function (Pgp)
cellular_component (Pgp)
Pgp (Mus musculus)
Pain Link Frequency Relevance Heat
Morphine 38 99.48 Very High Very High Very High
methadone 2 98.20 Very High Very High Very High
Opioid 16 85.68 High High
Oxycodone 22 79.80 Quite High
Codeine 6 60.92 Quite High
Glutamate 8 55.28 Quite High
Neurotransmitter 4 53.80 Quite High
positron emission tomography 8 33.04 Quite Low
Bioavailability 32 29.52 Quite Low
vincristine 4 21.00 Low Low
Disease Link Frequency Relevance Heat
Cancer 48 75.28 Quite High
Primary Sclerosing Cholangitis 12 70.40 Quite High
Drug Induced Neurotoxicity 4 65.44 Quite High
Toxicity 16 62.20 Quite High
Leukemia 4 20.20 Low Low
Cv Unclassified Under Development 8 14.84 Low Low
Disease 24 5.00 Very Low Very Low Very Low
Breast Cancer 10 5.00 Very Low Very Low Very Low
Adrenoleukodystrophy 4 5.00 Very Low Very Low Very Low
Hypoxia 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Although the exact site and number of Pgp binding with drugs have not yet been determined, the important binding sites such as TMD 4, 5, 6, 10, 11 and 12 have been determined [181] whereas substrate drugs do not bind to NBDs [182].


Pgp Binding (binding) of
1) Confidence 0.32 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC1277830 Disease Relevance 0.08 Pain Relevance 0
On the other hand, the flavonoid, kaempferide, is bifunctional in that it would partially block the binding of the antiprogestin RU-486 in the cytoplasm domain of Pgp and block ATP binding [195] (Fig. 4).
Pgp Binding (binding) of
2) Confidence 0.28 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC1277830 Disease Relevance 0.25 Pain Relevance 0
Although the exact site and number of Pgp binding with drugs have not yet been determined, the important binding sites such as TMD 4, 5, 6, 10, 11 and 12 have been determined [181] whereas substrate drugs do not bind to NBDs [182].


Pgp Binding (binding) of
3) Confidence 0.25 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC1277830 Disease Relevance 0.08 Pain Relevance 0
Pgp undergoes conformational changes upon binding of nucleotide to the NBDs [174].
Pgp Binding (binding) of
4) Confidence 0.24 Published 2005 Journal Cancer Cell Int Section Body Doc Link PMC1277830 Disease Relevance 0 Pain Relevance 0.11
Methadone is in the intermediate range in this respect, with a ratio of 2.6 regarding its possible Pgp interaction (79).
Pgp Binding (interaction) of associated with methadone
5) Confidence 0.13 Published 2007 Journal Pharm Res Section Body Doc Link PMC2469271 Disease Relevance 0 Pain Relevance 0.60
The associated ratio of 1.2 for morphine indicates a minute risk of interaction with Pgp substrates; morphine is also a substrate for probenecid-sensitive transporters (83).
Pgp Binding (interaction) of associated with morphine
6) Confidence 0.09 Published 2007 Journal Pharm Res Section Body Doc Link PMC2469271 Disease Relevance 0 Pain Relevance 0.65

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox